Datadog went public on Thursday and instantly hit a $10 billion valuation, becoming the fourth cloud software debut to reach that level this year.Technologyread more
Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
There are challenges with Iran, North Korea, the Afghan Taliban, Israel and the Palestinians — not to mention a number of trade pacts.Politicsread more
In perhaps Buffett's first televised profile, he explained a method of investing that prioritizes bargains and makes use of an occasional baseball analogy.Marketsread more
The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
A 58% majority of registered voters express unease about voting for Trump, but slightly more say the same about Joe Biden and Bernie Sanders, while Elizabeth Warren fares only...Politicsread more
Investors are asking how the world's third-largest defense spender could have left itself so vulnerable and what that means for the future.Politicsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
Solar power is on the rise. You can see the evidence on rooftops and in the desert, where utility-scale solar plants are popping up. The picture is not all rosy, but if the...Technologyread more
CNBC did a deep dive through the most recent Wall Street research to find stocks that analysts say are underappreciated.Marketsread more
- filings@ (Adds analyst comment, share movement)
Aug 30 (Reuters) - The U.S. patent office will review three patents on Alexion Pharmaceuticals Inc's drug Soliris, after rival Amgen Inc filed a petition challenging them, court filings showed on Friday.
The Patent Trial and Appeal Board, a court run by the U.S. patent office, said it was instituting an inter-party review on the patents.
Amgen is contesting the issuance of new Soliris patents in the United States that would extend the drug's market exclusivity to 2027.
Soliris is approved for two rare blood disorders, paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome. It brought in sales of $980.8 million for Alexion in the quarter ended June 30 and accounted for nearly 82% of the drugmaker's total revenue.
The drugmaker is trying to retain its stronghold in the PNH market and its Soliris-successor Ultomiris won U.S. approval for last year.
SVB Leerink analyst Geoffrey Porges said in a note a early launch of a cheaper rival for Soliris is likely to have an impact of $11 per share on Alexion. Shares of Alexion fell nearly 8%, or about $9, to $103.5 and those of Amgen rose 1% to $209.17 in early trading. (Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)